Cyclacel Pharmaceuticals Receives New Coverage from Analysts at Janney Montgomery Scott (CYCC)
Stock analysts at Janney Montgomery Scott initiated coverage on shares of Cyclacel Pharmaceuticals (NASDAQ:CYCC) in a report issued on Tuesday, TheFlyOnTheWall.com reports. The firm set a “buy” rating on the stock.
Separately, analysts at JMP Securities initiated coverage on shares of Cyclacel Pharmaceuticals (NASDAQ:CYCC) in a research note to investors on Tuesday, July 2nd. They set an “outperform” rating on the stock.
Shares of Cyclacel Pharmaceuticals (NASDAQ:CYCC) opened at 3.679 on Tuesday. Cyclacel Pharmaceuticals has a 52-week low of $2.75 and a 52-week high of $8.18. The stock’s 50-day moving average is $3.02 and its 200-day moving average is $3.94. The company’s market cap is $65.2 million.
Cyclacel Pharmaceuticals (NASDAQ:CYCC) last posted its quarterly earnings results on Wednesday, August 14th. The company reported ($0.10) earnings per share for the quarter. The company had revenue of $0.26 million for the quarter, compared to the consensus estimate of $0.03 million. Analysts expect that Cyclacel Pharmaceuticals will post $-1.41 EPS for the current fiscal year.
Cyclacel Pharmaceuticals, Inc (NASDAQ:CYCC) is a development-stage biopharmaceutical company engaged in the discovery, development and commercialization of mechanism-targeted drugs to treat human cancers and other serious disorders.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.